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Homeostasis of the human body depends on the immune system regulated via specific 
signaling pathways mediated by cytokines. Many cytokines exert their unique effect by 
the means of JAK/STAT signaling pathway. Janus Kinase (JAK) family of enzymes are 
tyrosine kinase proteins which include 4 members: JAK1, JAK2, JAK3 and TYK2. 
JAKs consist of four domains: FERM domain and SH2 domain, which are engaged in 
cytokine-receptor association, and two protein-kinase domains: a pseudokinase domain 
(JH2) and a canonical tyrosine kinase domain (JH1). Tyrosine kinase domain is respon-
sible for the catalytic activity of the protein whereas the pseudokinase domain was 
found to have an important role of negatively regulating the tyrosine kinase domain 
function. JAK kinases are recognized as pharmaceutical targets for treatment of numer-
ous myeloproliferative diseases as well as several types of blood cancer.  However, the 
structure and mechanism of JAK activation and inhibition are still elusive. To design 
effective pharmaceutical agents, it is of paramount importance to determine the differ-
ences in interdomain interactions between pseudokinase and catalytic domains of JAKS 
in health and disease. 
In this study, we apply a novel approach to studying the conformational dynamics be-
tween JH2 and JH1. Fluorescence resonance energy transfer (FRET) based on cyan flu-
orescent protein and new Tetra Cysteine labelling technology that relies on small biar-
senical FlAsH-EDT2 dye was used to study the orientational change in JH2-JH1 do-
mains in wild type and under function disruptive mutation, V617F. The FRET meas-
urements were performed in gamma2a cells by acceptor photobleaching. The results 
demonstrate an altered FRET efficiency in pathogenic constructs which suggests that 
V617F induces a conformational shift between JH2 and JH1 domains by increasing the 
distance between the C-terminus of JH1 and the 726-728 residues in the C-lobe of JH2 
which brings closer the insertion loop of JH1 domain towards the N-terminus of JH2. 
Such change might underlie the hyperactivatory effect of V617F mutation and disrup-
tion of inhibitory regulation by JH2. Translating our results into precise structural 
mechanism will help provide better understanding of JAK-specific architectural traits in 
intramolecular interactions and contribute to design of more effective and selective 
drugs. 
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1. INTRODUCTION 
Signal transduction is an essential mechanism for cellular survival that allows cells to 
react to environmental conditions, adopt and communicate. Cellular growth, differentia-
tion, metabolism and proliferation are all the result of cell signaling. Signal transduction 
is a cascade of biochemical events that involves numerous components. The cascade 
starts at a receptor protein, usually transmembrane, that is activated by an extracellular 
signal (ligand) (Kishimoto, Taga, and Akira 1994). Ligand binding induces a conforma-
tional change in the receptor protein leading to a signal transduction to a next compo-
nent of the signaling pathway. Enzymes have a primary role in the signal transduction 
pathways of modifying other proteins, commonly via phosphorylation, or of being mod-
ified. Other molecules can also be involved in the signal transduction, e.g. Ca2+, and are 
termed second messengers, acting as intermediates between enzymes. An important 
event of signal transduction is modification of gene expression patterns that lead to fur-
ther activation of protein effectors that finally change cell’s morphology or function. 
Homeostasis of the human body and its health depend on regulation of the immune sys-
tem.  Immunity and autoimmunity, host defense, inflammation and hematopoiesis regu-
lation occur via specific signaling pathways mediated by cytokines (O’Shea, Gadina, 
and Kanno 2011). Cytokines are a family of small soluble proteins, peptides or glyco-
peptides produced by different cell types, including cells of immune system and others, 
but primarily by helper T-cells and macrophages (Tayal and Kalra 2008; Zhang and An 
2007). Cytokines exhibit local and systemic activity by affecting the cells they were 
secreted by (autocrine), neighboring cells (paracrine) and very distant cells (endocrine) 
(Zhang and An 2007). Cytokines are classified based on their function, e.g. erythropoi-
etins, thrombopoietins or chemokines; secretion cells, e.g. monokines or lymphokines; 
and target cells, e.g. interleukins and some interferons (Cytokine sugnaling n.d.). In ad-
dition pro-inflammatory and anti-inflammatory cytokines are recognized (Zhang and An 
2007). Cytokines possess several distinct properties: pleiotropy (same molecules acting 
on different cells), redundancy (same function is induced by different molecules) and 
multifunctionality (same molecule induces different functions) (Tayal and Kalra 2008). 
As ligands cytokines bind to certain receptor proteins that are divided into six major 
family groups based on their structural homology: immunoglobulin receptors, interferon 
receptors (class II), tumor necrosis factor receptors, chemokine receptors, transforming 
growth factor receptors and hematopoietin receptors (class I) (Wang et al. 2009).  
Many cytokines, particularly class I and II receptor cytokines, exert their unique effect 
by the means of JAK/STAT signaling pathway. Cytokine receptors do not exhibit an 
intrinsic tyrosine phosphorylation activity, i.e. transferring a high energy γ-phosphate 
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from ATP to a substrate, unlike some tyrosine kinase receptors, for example insulin 
receptors (Babon et al. 2014). Therefore, other nonreceptor tyrosine kinase proteins are 
employed (Kishimoto et al. 1994; Rane and Reddy 2000). These tyrosine kinase pro-
teins belong to Janus Kinase (JAK) family of enzymes, which includes 4 members: 
JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase 2) (Babon et al. 2014). JAK kinases are 
monomers that consist of four main domains: amino-terminal band 4.1, ezrin, radixin, 
moesin (FERM) domain and a Src homology 2 (SH2) domain, which are engaged in 
specific receptor subunit association, and tandem kinase domains: a pseudokinase do-
main (JH2) as well as a tyrosine-kinase domain (JH1). Janus kinases received their 
names from a Roman god with two faces which is analogous to two alike kinase and 
pseudokinase domains in JAK proteins (Yamaoka et al. 2004). Upon ligand binding a 
cytokine receptor undergoes oligomerization which leads to juxtapositioning of nearby 
associated JAKS to form homo- or heterodimers and their activation (Wang et al. 2009). 
Activated JAK kinases phosphorylate the tyrosine residues on the cytoplasmic region of 
the receptor. These tyrosine residues comprise a conserved Scr homology site (SH2) 
which is recognized by signal transducer and activator of transcription (STAT) proteins 
(Babon et al. 2014; Finbloom and Larner 1995; Rawlings, Rosler, and Harrison 2004). 
Binding of STATs to the recognition site on the receptor results in their activation by 
JAK phosphorylation of the conserved tyrosine in the C-terminus of STATS (Rane and 
Reddy 2000; Rawlings et al. 2004). Activated STATs dimerize and translocate to the 
nucleus to affect the expression of specific genes by targeting DNA regulatory sequenc-
es (Rawlings et al. 2004; Wang et al. 2009).  
In the last few decades it has been identified that many malignancies originate from 
JAK/STAT pathway dysfunction and specific mutations in JAK kinases and STAT tran-
scription factors (Sun and Sun 2014). Mutations leading to disease development are 
usually characterized as gain-of-function or loss-of-function (O’Shea et al. 2011). Muta-
tions in the JAK bearing alleles result in inactive JAK3 and TYK2. For example,  non-
sense or frameshift mutations in pseudokinase domain of JAK3 result in truncation of 
the kinase and are loss-of function leading to X-linked severe combined immunodefi-
ciency (XSCID) (Boggon et al. 2005; Russell et al. 1995).  As shown by cancer genome 
sequencing somatic mutations in JAK1, JAK2 and JAK3 kinases are the primary cause 
in array of myeloproliferative neoplasms (MPN) and some number of solid tumors 
(Chen, Staudt, and Green 2012; Lupardus et al. 2014; O’Shea et al. 2011; Sun and Sun 
2014). Chronic myelogenous leukemia (CML), polycythemia vera (PV), essential 
thrombocythemia (ET), idiopathic myelofibrosis (IMF) and primary myelofibrosis 
(PMF) (Silvennoinen and Hubbard 2015) all belong to the myeloproliferative disorders 
group represented by elevated proliferation of different hematologic (blood) cell types, 
increase in proinflammatory cytokines levels, spleen enlargement and incapacitating 
syndromes (Haleem J. Rasool 2016; Verstovsek et al. 2012). The most characterized 
valine-to-phenylalanine mutation (shortly V617F or VF) in JAK2 (as well as analogous 
mutations in JAK1 and TYK2) results in increased phosphorylation of JAK2 substrates 
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and cytokine-independent signaling. It is found in 95% of PV patients and in 50-60% of 
ET patients and in some PMF patients (Hammarén et al. 2015; Klampfl et al. 2013). 
Interestingly, these three different diseases arise from just one mutation. Such phenom-
enon is attributed to what is now called allele burden of the mutation which is deter-
mined as a ratio between mutated and wilt type JAK2 (Passamonti and Rumi 2009). 
Different ‘dosages’ of mutant genes are characteristic of certain disease phenotypes. ET 
phenotype is induced by low dosage of VF mutant JAK2, whereas larger allele burden 
causes PV phenotype (Scott et al. 2006; Silver et al. 2011). Eventually, increase in allele 
burden leads to homozygous JAK2 and development of leukemia. That is why Janus 
kinases are attractive pharmaceutical targets and different suppressive drugs were de-
veloped in attempt to combat the diseases (Passamonti et al. 2008).  
1.1 JAK kinases 
JAK kinases are relatively large proteins consisting of more than 1100 amino acids and 
molecular weight of 120-140 kDa (Silvennoinen and Hubbard 2015; Yamaoka et al. 
2004). JAK kinases stretch over 7 regions of high sequence homology conserved in 
mammalian, avian, teleost and insect JAKs. These regions are called JAK homology 
(JH) domains, numbered 1 to 7 from carboxyl terminus to amino terminus (Figure 1) 
(Giordanetto and Kroemer 2002; Yamaoka et al. 2004). The 7 JH domains are divided 
into 4 bigger sites each having their own function. JH1 is a tyrosine kinase domain re-
sponsible for the catalytic activity of the protein. JH2 is called a pseudokinase domain 
because of its structural similarity to canonical kinases but inability to catalyze any re-
actions. Nearly 10% of kinases encoded by human genome lack essential for catalytic 
activity consensus sequences and are termed pseudokinases (Min et al. 2015). Neverthe-
less JH2 domain was found to have an important role of regulating the catalytic domain 
function by inhibiting its basal activity (Luo et al. 1997; Shan et al. 2014). According to 
earlier studies (Saharinen and Silvennoinen 2002; Saharinen, Takaluoma, and 
Silvennoinen 2000) mutations in the JH2 domain lead to abrogated activity of JH1 do-
main resulting in its hyperactivation and constitutive activity which is the primary cause 
for MPNs. Therefore, it can be said that pseudokinase domain of JAKs has a tumor-
suppressing function (Lupardus et al. 2014). JH3, JH4 and JH5 together comprise the 
Src homology-2 (SH2) domain whose role is yet unknown but might have a stabilizing 
role in JAKs conformation (Chrencik et al. 2010) and generally the domain acts as 
docking site for other tyrosine phosphorylated proteins. The final two N-terminal do-
mains, JH6 and JH7 form a Band-4.1, ezrin, radixin, moesin (FERM) domain 
(Kohlhuber et al. 1997; Yamaoka et al. 2004). FERM is generally around 300 amino 
acids long and is involved in receptor interactions. The amino-terminus of JAK proteins 
is essential for association with common type I and II cytokine receptors, such as hema-
topoietic growth factor receptors, erythropoietin receptors, interleukins (IL)-2, -3, -4, 
and -6 and granulocyte-colony-stimulating factor receptors (Giordanetto and Kroemer 
2002; Tanner et al. 1995).  JAK protein related receptors exhibit two conserved se-
quences about 8 amino acids long. These sequences carry names ‘box1’ and ‘box2’ and 
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are rich in proline residues. Studies show that mutations in box1 region prevent JAK 
from stable binding to the receptor and inhibit the downstream signaling (Tanner et al. 
1995; VanderKuur et al. 1994).  
Despite the successful attempts to purify full length JAK proteins (Duhé, Clark, and 
Farrar 2002; Ma and Sayeski 2004) the crystalized three-dimensional structure of full 
length JAKs is unavailable (Giordanetto and Kroemer 2002; Yamaoka et al. 2004). 
Several groups managed to crystalize separate domains of JAK kinases. For example, in 
2014 Lupardus and colleagues crystalized the kinase and pseudokinase domains of 
TYK2 shedding light on the molecular mechanism by which JH1 is regulated by JH2 
and that this regulation is autoinhibitory. A year before that Bandaranayake at al. pre-
sented a crystal structure of JAK2 wild type pseudokinase domain and with V617F mu-
tation and characterized their main structural differences.  In 2006 a crystal structure of 
JAK2 kinase domain was obtained by Lucet et al. In 2005 Boggon  and colleagues 
provided a crystal structure of JAK3 kinase domain and described its active 
conformation that is unique to JAKs family. And Chrencik et al.  characterized JAK1 
kinase domain in complex with potent pan-kinase inhibitors. However, the listed crystal 
structures are not of the native sequence or conformation. The wild type as well as apo 
(ligand unbound) structures could not be obtained, even if the protein could be ex-
pressed in baculovirus expression system and had good solubility. The structures pre-
sented are usually holo structures in conjunction with some protein kinase inhibitors or 
containing stabilizing mutations, such as D1023N in TYK2 conferring the kinase inac-
tive (Lupardus et al. 2014), or substitution of hydrophobic residues in solvent-exposed 
positions (Bandaranayake et al. 2012). Several theoretically generated 3D structures 
were also produced of the full length JAK2 and separately of its domains that are pre-
sented in Figure 2, A and B (Giordanetto and Kroemer 2002; Lucet et al. 2006; Shan et 
al. 2014). 
Structurally the catalytic domain of all typical protein kinases is greatly conserved and 
comprised of two lobes: N-lobe (residues 840-931 in JAK 2) and C-lobe (932-1132 in 
JAK 2) that surround the nucleotide binding site (Lucet et al. 2006) (Figure 2, A).  The 
N-lobe includes 5 antiparallel -strands, numbered 1 to 2, and one -helix (C) 
which is essential for catalytic activity in many kinases (Boggon et al. 2005).  The car-
boxyl-terminal is dominated by 8 -helices, named D through K, 3 shorter helices 
(3/10 B, C and D) and 6 more antiparallel -strands (7 through 11) (Lucet et al. 
2006). The connecting part between the two lobes is called a hinge region. Mg-ATP 
binds JH1 at the nucleotide binding cleft between two lobes which is characterized by a 
hydrophobic pocket harboring adenine base of Mg-ATP and a polar pocket interacting 
with ribose and coordinating triphosphates and magnesium (Chrencik et al. 2010). Like 
in other canonical protein tyrosine kinases (PTKs) the nucleotide-binding site of JH1 
contains a threonine and glycine residues that form hydrogen bonds with gamma and 
beta phosphates of ATP, respectively (Bandaranayake et al. 2012). The ATP interacting 
glycine is a part of what is called glycine or nucleotide-binding loop with a consensus 
sequence G-X-G-XX-G, where X stands for any other amino acid. A unique feature 
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observed only in JAK kinase family is an insertion loop situated between amino acids 
1056 and 1078 in JAK2. This loop is presumably involved in regulation of JAK activity 
through autophosphorylation or in intramolecular interactions with FERM domain 
(Boggon et al. 2005; Lucet et al. 2006). 
JH2 domain starts at 537 phenylalanine and ends at 808 leucine in all JAKs. The struc-
ture of JH2 domain of JAK kinases is highly similar to that of the JH1 domain (Figure 
2, B) with two lobes and in total 9 -helices and 8 -strands (Bandaranayake et al. 
2012). However, some essential features required for proper catalytic activity are miss-
ing. For example, JH2 domain of JAK2 has a 7 amino acids shorter glycine loop which 
is non-phosphorylatable and an aspartic acid is missing from the H-R-D motif in the 
catalytic loop of JH2 which is necessary for phosphorylation (Min et al. 2015). In JH2 
the aspartic acid is replaced by asparagine (Bandaranayake et al. 2012). In addition, the 
catalytic site was found to be abstracted by the activation loop which conformation is 
characteristic for typical pseudokinases (Toms et al. 2013). Furthermore, a loop between 
β7 and β8 strands in JH2 is eight amino acids longer than the respective loop in JH1 
(Bandaranayake et al. 2012). Nevertheless, unlike other members of JAK family JH2 of 
JAK2 was found to possess frail catalytic activity.  JAK2 JH2 phosphorylates in cis 
Ser523  in SH2-JH2 linker and in trans Tyr570 in the β2-β3 loop in JAK2 
(Silvennoinen et al. 2013). These residues are present only in JAK2 implying that the 
activation mechanism for this member of the JAK family is unique. Phosphorylation of 
these sites is assumed to play role in inhibition of JH1 by JH2 and to stabilize the inac-
tive conformation of JAK2 through electrostatic interactions with basic amino acids on 
JH1 (Figure 3) (Bandaranayake et al. 2012). The ability for nucleotide binding is pre-
served in JH2 of all the JAKs and is believed to act as a ‘molecular switch’ stabilizing 
the overall conformation of the domain and securing a specific orientation essential for 
molecular interaction (Babon et al. 2014). 
The N-lobe of JH2 domain (exon 12 and 14), β7-β8 loop (exon 16) and the linker be-
tween JH2 and SH2 domains harbor most of the function disruptive mutations. Numer-
ous mutations occur in exon 12, which starts at M535 and ends at F547. They include 
most common substitution of K539L and deletion of E543, others are described in detail 
in paper by Pietra et al. 2008.  V617F mutation is found in exon 14 of JH2 which 
stretches from S593 to I622 (Ma et al. 2010). The structural differences between wild 
type and mutated JAKs are quite minor. The V617F mutation in JAK2 is located in the 
N-lobe of JH2 in the loop between β4 and β5 strands proximal to αC-helix (Dusa et al. 
2010). Bandaranayake et al. (2012) identified that the αC helix in JH2-VF is more 
rigidified due to backbone hydrogen-bonding unlike its somewhat distorted 
conformation in JH2-WT and is longer by a turn at amino-terminus end. In JH2-VF 
three phenylalanines, F617, F595 and F594 in the middle of αC-helix in JAK2, form T-
shaped pi-stacking interactions. In other tyrosine kinases, e.g. Src and ZAP-70, such 
stacking was demonstrated to regulate the catalysis by those enzymes (Dusa et al. 
2010). Mutation of the phenylalanine at 595 (and F636 in JAK1) position to non-
aromatic amino acid disrupts the aromatic stacking interactions and the catalytic func-
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tion as well as hyperactivatory effect of V617F mutation decreasing its constitutive ac-
tivity even by 85%. Mutation of F595 to an aromatic amino acid, however, e.g. tyrosine 
or tryptophan, reconstitutes the full activity of JAK2 indicating that a bulky hydropho-
bic residue is essential for maintaining the hydrophobicity of the region and molecular 
interactions in the αC-helix (Dusa et al. 2010). 
 
 Linear structure of JAK kinase. JAK kinases consist of four main domains: 
FERM, SH2; JH2 and JH1. The FERM and SH2 domains are subdivided into 5 
smaller JAK homology domains. The site of phosphorylation upon JAK activa-
tion are marked with yellow stars. 
 
 (A) PyMOL ribbon diagram of JH2 (orange) and JH1 (green) domains, 
based on molecular dynamics simulations by Shan et al. 2014. (B) Differently 
oriented JH2 domain alone. 
1.2 Activation of protein tyrosine kinase 
Activation of JAK tyrosine kinases starts with ligand binding to cytokine receptor in-
ducing a conformational modification in the cytoplasmic region of the receptor leading 
to formation of multimeric aggregate. The receptor chains accumulation causes juxtapo-
sitioning of associated JAK monomers to form homo- or heterodimers (Saharinen and 
Silvennoinen 2002). Prior to ligand stimulation JH2 domain of JAK kinases is constitu-
tively phosphorylated in residues Ser523 and Tyr570 in JAK2. This substoichiometrical 
phosphorylation negatively regulates the basal activity of JAK kinase domain by stabi-
lizing the inactive conformation through interaction with positively charged residues on 
JH1 domain (Shan et al. 2014). Activation of JAK kinase requires phosphoryl transfer 
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to two tyrosine residues found in the activation loop (Tyr1007 and Tyr1008 in Jak2, 980 
and 981 in JAK3) of JH1 domain that play an influential role in regulation of JAK ki-
nase activity.  Suppressors of cytokine signaling (SOCS) and protein-tyrosine phospha-
tases (PTP1B and TCPTP) aim specifically at the activation loop and conserved tyro-
sine motif to inhibit the cytokine induced signaling (Saharinen and Silvennoinen 2002). 
The first tyrosine phosphorylation is mediated by lysine and arginine residues in C-helix 
f JH1 through water-guided hydrogen bonding (Boggon et al. 2005). Phosphorylation of 
both tyrosines causes the activation loop to be expelled from the catalytic site conferring 
an active conformation (Babon et al. 2014). Activated JAKs in turn are able to phos-
phorylate the tyrosine residues on the receptor allowing for further downstream signal-
ing. The precise activation mechanism, however, is still poorly understood. Two models 
are suggested in favor of in trans or in cis inhibition by JH2 domain and in trans or in 
cis phosphorylation of JH1 domain. The in cis autoinhibition mechanism was proposed 
for the crystalized structure of JH2-JH1 domains of TYK2. It suggests that the N-lobes 
interactions between pseudokinase and kinase domains rigidify the hinge region be-
tween C- and N-lobes in JH1 hindering its elasticity and preventing the orientation of 
C-helix and other catalytic elements into a position ready for catalytic reaction 
(Lupardus et al. 2014). A different mechanism was proposed for JAK2 activation based 
on SAXS analysis that demonstrated an elongated structure of JH2-JH1 domains indica-
tive of insufficient proximity for in cis inhibition (Babon et al. 2014). Another study by 
Brooks et al. 2014 of growth hormone receptor and its two associated full length JAK2 
reveals that upon ligand binding the intercellular part of the receptor undergoes a sepa-
ration causing the pseudokinase domain to detach from opposing kinase domain and 
allowing two kinase domains to come in close vicinity for trans phosphorylation. Con-
sidering that JAK2 possesses two unique sites in JH2 that are constitutively phosphory-
lated and deemed to be responsible for stabilizing the inhibited state it is presumable 
that the activation mechanisms are not universal for the JAK kinase family and both 
models have a right for existence. It is good to point out that two more domains are pre-
sent in JAKs that might affect the mode of autoinhibition and activation as well as the 
different receptors that JAKs associate with. 
1.3 JAK kinase inhibitors 
The structure of the catalytic domain in all kinase proteins is highly conserved, that is 
why it was initially thought that use of kinase targeted therapeutical agents would be 
accompanied by high toxicity. Furthermore, because the common approach to develop-
ment of novel drugs was design of competitive ATP inhibitors the prospects of develop-
ing selective kinase inhibitors seemed dim. Nevertheless, after long clinical trials there 
are present 13 FDA-approved kinase inhibitors on the market today (Kontzias et al. 
2012). In some cases, the issue with structural similarity was addressed by targeting the 
kinase superfamily in their inactive conformation that is distinct among them. The fact 
that the gate-keeper amino acid in the catalytic sites of kinase domains differs among 
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kinases was exploited to develop specific kinase antagonists (Pesu et al. 2008). Howev-
er, it turned out that development of strictly specific kinases inhibitors was not required 
for potent and safe drugs. Numerous kinase antagonists such as dasatinib, sunitinib, 
sorafenib and others have multiple targets in their mode of action in treatment of cancer 
and other malignances and such broad applicability provided some unexpected bene-
fits.(Pesu et al. 2008).  
The first drug specifically targeted to JAK kinase family which was approved for trials 
in humans was tofacitinib (CP-690,550) (Ghoreschi et al. 2011). Tofacitinib had signifi-
cant potency for JAK3, JAK1, some for JAK2 and next to no effect in other kinases 
(Kontzias et al. 2012; O’Shea et al. 2013). Tofacitinib proved efficacious against aller-
gic diseases and blockade of proinflammatory cytokine production to combat immuno-
logical and inflammatory diseases proving especially effective in treatment of rheuma-
toid arthritis (RA) and can soon be approved for administration to RA patients. Howev-
er, due to its wide mode of action its side effects included impeded erythropoietin sig-
naling which can result in anemia and neutropenia, as well susceptibility to various in-
fections (Kontzias et al. 2012; Zand et al. 2013). After that several other FDA-approved 
JAK inhibitors emerged into the market for treatment of rheumatoid arthritis, psoriasis, 
inflammatory bowel disease and transplant rejection. Ruxolitinib and baracitinib 
(INCB028050) are JAK1/JAK2 antagonists designed for treatment of myeloprolifera-
tive disorders in intermediate and high risk groups but also showed promising results in 
RA treatment studies (Deininger et al. 2015; O’Shea et al. 2013). Due to similar mecha-
nism of action as of tofacitinib, which blocks many of the cytokines involved in innate 
immune response, ruxolitinib and baracitinib have similar side effects including anemia 
and thrombocytopenia (Verstovsek et al. 2012). It was also recently shown that the ef-
fect of these drugs, in particular for ruxolitinib, differs with time. In short-term follow-
up studies the allele burden of JAK2 V617F mutation was not affected by therapy with 
ruxolitinib (Silver et al. 2011), whereas another study demonstrated a considerable re-
duction in allele burden as well as other symptoms, such as splenomegaly, in long-term 
follow-up studies (Deininger et al. 2015). 
Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) are targeted 
with imatinib, sunitinib, nilotinib (AMN107) and dasatinib (BMS-354825). The CML 
and ALL are cause by constitutively active tyrosine kinase mutant that is translated 
from an oncogenic fusion gene BCR-ABL. The BCR-ABL gene is a result of fusion 
between c-ABL and breakpoint cluster gene (BCR) due to translocation of human 
chromosome 9 and 22 (Tokarski et al. 2006). Imatinib showed high potency against 
early stage CML, but not advanced, by inhibiting kinase activity of mutant tyrosine ki-
nase. Surprisingly, however, resistance to imatinib treatment is acquired during any 
stage of the disease due to point mutations at the imatinib binding site in inactive kinase 
domain of mutant tyrosine kinase (Tokarski et al. 2006). Such resistance was addressed 
by dasatinib which proved 325-fold more efficacious (O’Hare et al. 2005). Higher effec-
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tivity of dasatinib is due to its capability to bind to both inactive and active confor-
mations of the kinase, which demonstrates importance of conformation considerations 
in drug design (Tokarski et al. 2006). 
1.4 Fluorescent proteins  
In the last few decades the advancement in cell biology research was achieved greatly 
due to the development of fluorescent proteins (FP). Genetically encoded fluorescent 
labels enabled the study of biomolecules and biological processes under physiological 
conditions in their native environment with non-invasive measurement technologies. A 
great deal of effort was dedicated to engineering of fluorescent proteins with enhanced 
properties, sensing abilities and increased stability (Abraham 2015). Numerous color 
variants of fluorescent proteins were engineered to allow visualization of cellular interi-
or in blue to near-infrared range of spectrum (Figure 4, A). Fluorescent switches, optical 
tweezers, photoactivable FPs, fast-maturing FPs, cell clocks and timers are some of in-
credibly many tools available for studying cellular organelles and biomolecules’ struc-
ture and dynamics in spatial temporal manner (Chudakov et al. 2010; Lukyanov et al. 
2005).  
The first fluorescent protein, green fluorescent protein (GFP), was derived from jelly-
fish Aequorea Victoria. In A. Victoria the GFP exists together with photoprotein ae-
quorin in a photogenic organ (Shimomura 1979). Aequorin produces energy required 
for excitation of GFP via Ca2+ triggered biochemical reaction and passes that energy to 
GFP via Föster-like energy transfer mechanism (Shimomura 1979). GFP molecular 
weight is 27 kDa with primary structure consisting of 238 amino acids (Abraham 2015). 
The tertiary structure of GFP is represented by a beta barrel formed by 11 antiparallel β-
strands (Chudakov et al. 2010). A distorted α-helix is located along the central axis of 
the barrel (Figure 4, B). The helix contains three essential amino acids that comprise the 
main fluorophore:  Ser65, Tyr66 and Gly67 (Abraham 2015; Crone et al. 2013). Thanks 
to beta-barrel structure GFP is a highly stable protein resistant to proteolysis and chemi-
cal and thermal denaturation (Abraham2015; Chudakov et al. 2010). 
Among naturally occurring fluorescent proteins the amino acids at residues 66 and 67 
are conserved, whereas the Ser65 residue varies conferring distinct color homologs. The 
wild-type variant of GFP was a subject to mutagenesis due to its poor fluorescence at 
green emission wavelength and brighter fluorescence in UV region of spectrum which 
is toxic to cells (Heim, Cubitt, and Tsien 1995). Serine to threonine mutation at residue 
65 conferred a brighter and more stable green fluorescent protein (excitation/emission – 
489/509) which was used as foundation for further development (Abraham 2015). Two 
mutants were created based on GFPS65T: GFPmut1 and enhanced GFP (EGFP; excita-
tion/emission – 488/509) by replacement of phenylalanine at 64 to leucine and codon 
optimization for expression in bacterial and human cells, respectively (Yang, Moss, and 
Phillips 1996). Further substitution of tyrosine 66 to histidine resulted in blue fluores-
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cent protein (excitation/emission – 382/459) and additional substitution of 145 tyrosine 
to phenylalanine yielded an enhanced blue fluorescent protein (EBFP; excita-
tion/emission – 380/460) (Heim et al. 1995; Yang et al. 1996). Because the excitation 
wavelength of BFPs is near UV radiation region, irradiation of cells at that wavelength 
is toxic. This and other shortages of BFPs hinder its usability in research. Cyan version 
of GFPs was created by Y66W mutation and then improved to obtain an ECFP (excita-
tion/emission – 434/477; (Heim et al. 1995)). Fluorescent properties of CFP were very 
inferior in comparison to other engineered FPs, however due to its spectral overlap with 
YFP, CFP is widely used in fluorescent resonance energy transfer applications (Abra-
ham 2015). Citrine is the most used homolog of EGFP engineered by S65G, V68L, 
S72A and T203Y mutations. Red variants of FPs, however, could not be derived from 
GFP protein engineering. That is why the search for red fluorescent proteins among 
Anthozoa species and corals continued until a plethora of red, far-red and orange FPs 
was discovered (Shcherbakova et al. 2012). mCherry is a modified variant of first RFP 
mutants which is a monomer with great photostability and is widely used in current cell 
imaging applications (Abraham 2015). 
 
 
  A) Color homologs of fluorescent proteins with accentuated central 
chromophore (CC license). B) Representative 3D image of GFP beta-barrel 
with fluorophore shown in stick and ball style. The central alpha-helix is shown 
in purple. The dimensions of GFP are 40 Å long and 30 Å wide (CC license). C) 
Molecular structure of FlAsH-EDT2 with its dimensions in Ångströms (CC li-
cense). 
1.5 Tetracysteine tag technology 
Investigation of proteins of interest (POI) in living cells requires that the native function 
and structure of POIs are preserved. However, FPs are considerably large biomolecules 
that, to their disadvantage, can perturb the functional conformation of target proteins. 
Yet any alterations of fluorescent proteins structure leads to the loss of their fluorescent 
properties (Wombacher and Cornish 2011).  
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Attempts were made to reduce the substantial size of FPs by introduction of protein 
chemical tags. A HaloTag, 30 kDa protein tag, is a slightly altered haloalkane dehalo-
genase engineered for covalent binding of synthesized ligands (Los et al. 2008). It is 
responsible for removal of the alkyl group from alkylhalides and its covalent binding to 
the asparagine residue in enzyme’s active site. Mutation of histidine at residue 289 cre-
ates a self-modifying HaloTag resistant to hydrolysis of covalent bond with alkyl-
fluorophore conjugate (Los et al. 2008). Another development is O6-alkylguanine-
DNA-alkyltransferase (hAGT) tags of ~20 kDa size that can be labelled with O6-
benzylguanine derivatives conjugated with plethora of fluorescent probes to study 
membrane as well as intracellular proteins (Gautier et al. 2008; Maurel et al. 2008). 
hAGT is a DNA repair enzyme engaged in catalysis of cytotoxic alkyl group at O6-
locus in guanine to its own cysteine residues (Keppler et al. 2002). Modification of O6-
benzyl guanine by attachment of fluorophore results in self-catalyzed labeling of hAGT 
at its active site. Protein engineering of hAGT allowed to obtain two highly specific 
tags: SNAP-tag and CLIP-tag that can be fused to POI for substrate-probe conjugate 
labeling (Johnsson et al. 2011; Keppler et al. 2006). Some of further discoveries include 
a fusion protein dihydrofolate reductase from E.coli, which is 18 kDa protein that can 
be specifically tagged with trimethoprim derivatives (Hoffmann et al. 2010; Miller et al. 
2005); and a acyl carrier protein (approximately 10 kDa) that can be used for selective 
labeling of surface proteins with synthetic fluorophore compounds (Nathalie George et 
al. 2004).  
All the above listed strategies are still considerably large. More radical steps of reducing 
the size of genetically encoded reporters lead to development of peptide chemical tags. 
A peptide chemical tag is a short peptide sequence that can be specifically targeted with 
a chemical fluorescent compound or be fluorescent on its own. The chemical fluores-
cent label can interact covalently with the peptide sequence by self-modification or 
through enzyme intermediate, or non-covalently via high-affinity interactions. Most 
important properties of small chemical tags should include specificity, minimal molecu-
lar weight, high signal to noise ratio, membrane permeability and low cytotoxicity. Pep-
tide tags are advantageous to protein tags due to their small sizes, as little as 2-3 kDa, 
however specificity of labeling is challenged and can only be improved through enzyme 
mediated labeling. (Wombacher and Cornish 2011) 
Some other approaches in selective chemical labelling were implemented, such as in-
corporation of unnatural amino acids (Lang and Chin 2014), yet peptide based chemical 
tags remain the most exploited techniques. To date, the most successful applications of 
peptide chemical tags were shown with tetracysteine-tag and oligohistidine/nickel com-
plex systems, both reliant on metal-chelation (Soh 2008). Commonly known as His-tag, 
an oligohistidine sequences consist of 6 to 10 histidine residues. They are characterized 
by high affinity interactions with nickel and nitrilotriacetic acids (NiNTA) complexes. 
Apart from broad applications in protein purification technology His-tag system showed 
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some promising results in selective chemical labelling (Bäumle et al. n.d.; Lata et al. 
2006).  
The first description of tetracysteine-tag technology was presented by Griffin, Adams, 
and Tsien in 1998. Their design was based on affinity of arsenoxides (R – As = O) to a 
couple of adjacent cysteines (Griffin, Adams, and Tsien 1998). In order to increase 
specificity and reduce cytotoxicity a bis-arsenical fluorescein probe (4’,5’-bis(1,3,2-
dithioarsolan-2-yl), Fluorescein Arsenical Helix binder (FlAsH), shown in Figure 3, C, 
was invented with two arsenoxides to target 4 closely-spaced cysteines (Wombacher 
and Cornish 2011). To further eliminate unspecific binding, labelling with FlAsH can 
be carried in presence of 1,2-ethanedithiol (EDT). EDT is a disulfide bonds reducing 
agent that interacts with FlAsH more stably than single cysteine pairs acting as a ar-
senoxides antidote (Griffin, Adams, and Tsien 1998). Complex of FlAsH and EDT – 
FlAsH-EDT2, can penetrate the cell membranes and becomes fluorescent upon binding 
to consensus sequence of tetracoordinate arsenic group CC-XX-CC, where XX is any 
amino acid. The most optimal and utilized sequence is CC-PG-CC. The binding motif 
can be inserted at various locations of POI, at either termini or in helical structures 
(Griffin et al. 1998; Soh 2008).  
FlAsH is a yellow fluorescent label with excitation/emission of 508/528 nm. FlAsH 
consists of two arsenic moieties bound to the xanthene ring of the fluorescein molecule. 
Derivatives of different colors were designed to enable simultaneous labeling and widen 
their applications in cell imaging. ReAsH is red colored bis-arsenical dye with excita-
tion/emission of 593/608 nm and CHoXAsH is blue fluorescent molecule with excita-
tion/emission of 380/430 nm (Soh 2008) and others including red BArNile. Improve-
ments of FlAsH fluorescent properties led to development of di- and tetrafluorinated 
FlAsH (F2FlAsH and F4FlAsH). These two derivatives are superior to FlAsH in many 
physical aspects, such as better absorbance, higher quantum yield, better photostability, 
in fact 50 times higher, and others. Additionally, F4FlAsH excites at 528 nm and emits 
light at 544 nm, which is an intermediate region in visible light spectrum between 
FlAsH and ReAsH creating a new color variant (Soh 2008; Spagnuolo, Vermeij, and 
Jares-Erijman 2006). F2FlAsH and F4FlAsH as well as FlAsH and ReAsH can be uti-
lized as donor-acceptor pairs for fluorescence resonance energy transfer (FRET) exper-
iments (Soh 2008). Another improved analog of ReAsH that can act as a FRET partner 
for FlAsH is AsCys3. The advantage of using AsCys3 is a longer interatomic distance 
between two arsenic atoms, particularly 14 Å in comparison to 6 Å between ReAsH 
arsenic moieties. It is thought to allow more selectivity when multiple reporters are used 
to label several POI (Haishi Cao et al. 2007). AsCys3 binds CCKAEAACC with high 
affinity (Kd = 80 ± 10 nm) with red-shifter emission values of 568-576 nm (Haishi Cao 
et al. 2007; Soh 2008). The consideration of rigid structure between two arsenical spe-
cies in FlAsH dyes and consequent limitation in fluorophore choice led to a new engi-
neering design where the xanthene ring acts as anchoring point between arsenic atoms 
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and a fluorophore. Such structure, collectively called as SplAsH, enables generation of 
multiple color homologs, such as SplAsH-Alexa594 and many others (Bhunia and 
Miller 2007). 
Advancement in engineering of bis-arsenical labels and chemical tags created a remark-
able toolbox for bioanalytical research. It was possible to achieve specific visualization 
of two RNA polymerase subunits from whole cell lysate (Chen et al. 2007). Tour et al. 
(2007) were able to precisely monitor calcium ion fluxes through gap junction by gen-
erating a Ca2+ indicator with impressive affinity and kinetics. Despite some drawbacks 
of first FlAsH dyes, modern FlAsH derivatives possess some outstanding properties and 
can make significant contribution to progress in cell biology research. 
1.6 FRET fundamentals 
Fluorescence resonance energy transfer, also known as Föster resonance energy trans-
fer, is a powerful technique that enabled numerous discoveries in biology, chemistry 
and other disciplines. In fact, the optimal FlAsH binding motif was identified by the 
means of FRET between GFP and ReAsH bound to randomized sequences containing 
four cysteine residues (Soh 2008). FRET is a phenomenon that arises from intrinsic 
property of a fluorophore in excited state to transfer its energy to another fluorophore 
instead of emitting a photon (Figure 4, A). Provided that a sufficient overlap of emis-
sion/excitation spectrum, J (λ) exists between two fluorophores the energy accepting 
fluorophore will become fluorescent (Figure 4, C; (Hussain n.d.; Sekar and Periasamy 
2003; Abraham 2015).  
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 FRET explained. A) Jablonski diagram of FRET (CC license). A fluores-
cent molecule exists in a ground state before excitation. When energy is applied, 
a fluorophore is excited to a higher energy level, e.g. S1. An electronic energy 
level has different vibrational levels. If a fluorophore rises to a higher vibra-
tional level of S1 it quickly undergoes relaxation through internal conversion to 
the lowest singlet excited state. Energy lost in relaxation process is the reason 
for wavelength difference between absorption and emission, which becomes red-
shifted. Presence of another fluorophore with appropriate absorption spectrum 
will cause immediate quenching of donor’s fluorescence and own excitation 
from ground state and photon emission. (Abraham 2015); B) FRET efficiency 
inverse dependency on distance between donor and acceptor. The Föster’s criti-
cal distance is shown as R0 (Modified from figure adapted with permission of 
Macmillan Publishers Ltd., © 2008, from (Roy, Hohng, and Ha 2008)) C) Do-
nor and acceptor’s fluorescence peaks shown with J (M-1cm-1), the spectral 
overlap of donor’s emission wavelength and acceptor’s absorption wavelength 
integrand 
The process of energy transfer occurs nonradiatively due to long distance dipole-dipole 
coupling between two molecules. FRET phenomenon is distance dependent and takes 
place more efficiently within 10 nm radius (10-100 Å). The distance at which the FRET 
efficiency is 50% is called Föster’s critical distance, indicated as R0, and is dependent 
on spectroscopic properties of donor-acceptor pair (Figure 4, B; (Sekar and Periasamy 
2003)). FRET is also dependent on the transitional orientation of two fluorophores rela-
tive to each other. Therefore, the efficiency of the energy transfer is calculated based on 
the distance separating two fluorochromes which is raised to the inverse sixth power 
due to the orientation of the donor emission dipole moment with acceptor’s excitation 
dipole moment (Periasamy, Day, and American Physiological Society 2005). 
𝐸 =  
(𝑅0)
6
(𝑅𝑜)6 + (𝑅)6
,                                                           (1) 
Formula 1 relates the separation distance between two fluorophores to the energy trans-
fer efficiency (Gu et al. 2004; Visser, Vysotski, and Lee 2011), where R0 is the Förster’s 
critical distance. R0 can in turn be evaluated by the following formula:  
𝑅0 = √0.2108[𝑘2𝑄𝐷𝑛−4𝐽]
6
,                                                (2) 
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where QD is the quantum yield of the donor fluorescence without acceptor. The quan-
tum yield of mTurquoise Cyan fluorescent protein is 0.84 (Goedhart et al. 2010). As a 
remark, the quantum yield for 250 nM FlAsH bound to tetracysteine motif in phos-
phate-buffered saline at pH 7.4 is 0.49. k2 is dipole orientation factor. It depends on the 
angle between fluorophores, but is often assumed to be 2/3. n is refractive index of in-
tervening medium, which could be approximated to the refractive index of water equal 
to 1.330. By using a salt solution dissolved in water the refractive index can be rounded 
to 1.4 (Visser et al. 2011). Finally, J (M-1cm-1nm4) is the spectral overlap of donor’s 
emission wavelength and acceptor’s absorption wavelength integrand. J depends on the 
molar extinction coefficient which for FlasH-EDT2 was determined in the range from 
30000 to 80000 M-1cm-1 (Griffin et al. 1998). The molar extinction coefficient of YFP is 
62000 M-1cm-1 (Adams et al. 2002). J also is dependent of the cumulative of donor’s 
emission spectrum normalized to the area of 1 and can be calculated using formula 3. 
 𝐽(𝜆) = ∫ 𝐹𝐷(𝜆)𝜀𝐴(𝜆) 𝜆
4𝑑𝜆,                                                    (3) 
where 𝐹𝐷(𝜆) is wavelength function of donor emission, 𝜀𝐴(𝜆) is wavelength function of 
acceptor excitation (Abraham 2015). 
A common method used to identify the distance separating two fluorophores based on 
the measured FRET efficiency is lifetime measurements or time resolved fluorescence 
measurements (Abraham 2015). A lifetime of fluorescent molecule represents the time 
it remains in the excited state before returning to the ground state. If no energy transfer 
occurs the fluorophore returns to it ground state slower (formula 4). If, however, another 
fluorophore is present the donor fluorophore drops to the ground state faster. The rela-
tionship between FRET represented as a rate of energy transfer and lifetime of a fluo-
rescent molecule can be seen in formula 5. 
𝜏𝐷 =
1
(𝑘𝑟 + 𝑘𝑛𝑟)
,                                                                 (4) 
𝜏𝐷𝐴 =
1
(𝑘𝑟 + 𝑘𝑛𝑟 + 𝑘𝑡)
,                                                                 (5) 
where kr is the rate of radiative decay, knr is the rate of nonradiative decay and kt is the 
rate of energy transfer. Based on the difference between the lifetime of a fluorophore 
with and without the influence of energy transfer the real FRET efficiency can be calcu-
lated as follows: 
𝐸 = 1 −
𝜏𝐷𝐴
𝜏𝐷
,                                                                 (5) 
The most utilized approach to FRET measurements, though, is steady state measure-
ments. The reason for higher preference among investigators is the possibility to use a 
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conventional confocal or fluorescence microscope as well as steady-state spectrofluo-
rometer (Abraham 2015). This way of FRET determination received its name due to the 
fact that when a sample is excited a steady-state among the fluorophores in the excited 
and ground energy levels is achieved in nanosecond time. The intensity, therefore, of 
the fluorescence is detected in steady state (Periasamy et al. 2005). The fluorescence 
measurements can be carried out as measurements of sensitized emission by either two-
channel or spectral imaging or as measurements by acceptor photobleaching. The basis 
for sensitized emission analysis lies in direct registration of the donor and/or acceptor 
fluorescence in presence of each other after excitation of donor. Occurrence of FRET is 
evaluated by the decrease in donor fluorescence in presence of acceptor (Berney and 
Danuser 2003). Acceptor photobleaching relies on the fact that the fluorescence intensi-
ty of donor fluorophore is quenched in the presence of acceptor. If the acceptor fluoro-
phore is subjected to photobleaching the donor fluorescence is recovered (Abraham 
2015).  
To gain valuable quantitative information from FRET measurements it is essential to 
generate appropriate controls and evaluate the bias caused by bleed-through in excita-
tion and cross-talk in emission. Such biases arise from signal interference between ac-
ceptor excitation with donor excitation and donor emission with acceptor emission and 
are often difficult to separate (Berney and Danuser 2003). Qualitative measurements 
with a purpose of assessment of apparent protein-protein interactions, however, can be 
obtained without excessive controls and are a means by which the aim of this study is 
achieved. 
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1.7 Aim 
 
Treatment of diseases caused by mutations of JAK kinases for years has been accom-
plished by the means of type I JAK inhibitors. Type I JAK inhibitors bind catalytic 
ATP-binding site in the active conformation of the kinase. Despite some positive results 
in disease treatment the activity of type I inhibitors increases autophosphorylation lead-
ing to some adverse downstream signaling. In expectation of more effective results type 
II inhibitors were developed targeting the JAK kinase domain in an inactive confor-
mation. Yet, neither of the aforementioned pharmaceutical agent groups were able to 
completely prevent the detrimental effects of JAK kinase mutations. In order to design 
effective pharmaceutical drugs, which can differentiate between active and inactive 
states of JAK kinases as well as mutant vs wild-type, it is of paramount importance to 
determine the three-dimensional structure of JAKS as well as activatory/inhibitory 
mechanisms of pseudokinase and kinase domains.  
The aim of this study is to conduct a qualitative analysis of JAK2 pseudokinase and 
kinase domains interactions in health and disease. By creating JAK2 JH2-JH1 DNA 
constructs fused with fluorescent tags we perform Fluorescence Resonance Energy 
Transfer (FRET) measurements in vitro and in live cells by acceptor photobleaching and 
time lapse imaging. To preserve the functional and structural integrity of the target pro-
tein we used a tetracysteine tag technology, which is the smallest genetically encoded 
tag capable of site-specific labelling inside living cells. FlAsH-EDT2 and cyan fluores-
cent protein are used as a FRET pair. The labelling procedure is methodically optimized 
for our specific constructs and cells. This approach has never been implemented in the 
study of JAK kinases. Such knowledge could bring us closer to visualizing the structur-
al changes in pathogenic and wild type JAK2 kinase and possibly contribute to devel-
opment of novel drugs specific for mutant JAKs. 
 
 
 
18 
2. METHODS AND MATERIALS 
2.1 Cloning and constructs generation 
Ten DNA constructs with and without V617F mutation were created. The DNA se-
quence of JH2-JH1 was fused with cyan fluorescent protein (CFP) and inserting tetra-
cysteine motif at three different loci. The JH2-JH1 sequence starts at 535 methionine 
followed by 536 valine and ending with 1132 glycine followed by a stop codon. The 
JH2-JH1 sequence is presented in Table 1, Appendix A. Construct 1 +/- VF, construct 2 
+/- VF, construct 3 +/- VF and corresponding controls are shown in Figure 4. In con-
structs 1 and 3 the CFP is fused without a linker to the amino-terminus of JH1, in con-
struct 2 CFP is fused to the carboxyl terminus of JH2. An optimized tetracysteine se-
quence was identified for efficient labelling with FlasH-EDT2 where four cysteines are 
separates by a proline and glycine motif – CCPGCC (Adams et al. 2002). In construct 1 
the tetracysteine motif was added right before 536V without a linker preceded by a start 
codon. In construct 3 CCPGCC sequence was inserted in JH2 domain at position be-
tween N726 and K728. The asparagine and lysine were replaced with two terminal cys-
teines of CCPGCC sequence and the proline between N and K is completely removed 
so that the protein is only 3 amino acids longer as such: K726C-CPGC-N728C. In con-
struct 2 the tetracysteine motif is inserted in a similar manner so that the 1053 lysine 
and 1055 are replaced with cysteines and 1054 serine is removed and CPGC is inserted: 
K1053C-CPGC-K1055C. The DNA sequence for tetracysteine binding site was tgt tgc 
ccg ggc tgc tgt harboring a Sma1 restriction site in ccg ggc for verification of insertion. 
The controls are JH2-JH1-CFP constructs without CCPGCC motif. All constructs con-
tained a thrombin cleavage site followed by a 6 x His tag for protein purification with 
Nickel beads.  
The constructs were generated by the means of overlap extension PCR (soePCR) for 
introduction of CFP and QuickChange site-directed mutagenesis (Stratagenes) for intro-
duction of tetracysteine sites and VF mutation. In soePCR sequences are amplified so 
that an overlap region is created. The sequences are then joined by complementarity in 
the first 10 cycles after which primers are added and the whole sequence is amplified. In 
site-directed mutagenesis the primers contain a target mutation and complements to the 
original sequence on both sides of the mutation. The whole plasmid is amplified with 
forward and reverse primers after which the original sequence is digested by Dpn1 re-
striction enzyme which is able to distinguish the new sequence due to a nick caused by 
PCR. Construct 1: human wild type JAK2 was amplified from 536 to 1132 residues 
with forward primer - tatagtcgacatgtgttgccctggctgctgtatggtgtttcacaaaatcag (1) including 
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start codon, tetracysteine sequence and Sal1 restriction site and reverse primer - 
ctcgcccttgctcaccattccagccatgttatcccttatttg creating an overhang with CFP. CFP sequence 
was amplified with forward primer - ggatcaaataagggataacatggctggaatggtgagcaagggcgag 
creating an overhang with JH1 and reverse primer - tatagcggccgctcag-
tggtgatggtgatgatggctgccgcgcggcaccagcttgtacagctcgtccatgccgag (2) including thrombin, 
His tag and Not1 restriction site. The sequences are joined in soePCR and amplified 
with (1) and (2). Construct 3: human wild type JAK2 was amplified from 536 to 1132 
with forward primer - tatagtcgacatggtgtttcacaaaatcagaaatgaa containing a start codon 
and Sal1 site and a reverse primer - ctcgcccttgctcaccattccagccatgttatcccttatttg creating 
an overhang with CFP. The same CFP amplicon was used for construct 3. The tetracys-
teine motif was inserted with forward primer - gaatgcattgaatgttgcccgggctgctg-
taatttaaatttggcaacagacaaatg and reverse primer - gccaaatttaaattacagcagcccggg-
caacattcaatgcattcaggtggtacccatgg. Construct 2: JH2-JH1 sequence was generated by 
amplification with forward primer - ctcggcatggacgagctgtacaa-
gatggtgtttcacaaaatcagaaatgthat creates an overhang with carboxyl-terminus of CFP and 
reverse primer - tatagcggccgctcatccagccatgttatcccttatttgatcc (3) that inserts Not1 re-
striction site. CFP was amplified with forward primer - tatagtcgacatgcatcatcaccatcac-
cacctggtgccgcgcggcagcgtgagcaagggcgaggag (4) introducing a Sal1 restriction site, 
6xHis tag and a thrombin cleavage site, and a reverse primer catttctgattttgtgaaacac-
catcttgtacagctcgtccatgccgag creating a JH2 overlap region. The CFP and JH2-JH1 am-
plicons were extended in soePCR with (3) and (4). The tetracysteine motif was inserted 
with forward primer - cacatacattgagtgttgcccgggctgctgtagtccaccagcggaatttatgcgtatg and 
reverse primer - cgctggtggactacagcagcccgggcaacactcaatgtatgtgaaaagttcatacag. The VF 
mutation was introduced with the following primers: atggagtatgtttctgtggagacgagaa-
tattctgg and tcgtctccacagaaacatactccataatttaaaacc.  
The constructs were cloned into pFastBac1 (Invitrogen) plasmid for insect cell culture 
and into pEGFP (Addgene) plasmid for mammalian cell culture. The constructs were 
restricted at Sal1 at 5’ and Not1 at 3’ restriction sites with Sal1 and Not1 fast digest 
enzymes (Thermo Fisher Scientific, FD0644, FDo593) and ligated with T4 DNA ligase 
(BioLabs, M0202S). PCR and restriction reactions were followed by gel electrophoresis 
for DNA purification and enzyme removal. The ligation product was heat inactivated 
for 10 minutes at 60 ºC and then directly transformed into XL1Blue cells. Five to ten 
colonies were picked for miniprep DNA extraction. Cloning was verified by restriction 
reaction and sequencing with Big Dye Terminator v1.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA). Midipres of the verified constructs were created and di-
luted to the final concentration of 200 ng/µL. 
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 Linear representation of tested constructs.  
2.2 Protein expression and purification 
The constructs and their controls were expressed with Bac-to-Bac expression system in 
baculovirus-infected Spodoptera frugiperda-9 (SF9) cells. The pFastBac plasmids with 
constructs of interest were transformed into DH10Bac E.coli strain where a recombinant 
baculovirus shuttle vector (bacmid) bMON14272 (138 kb) was generated by transposi-
tion of mini-Tn7 site in pFastBac with mini-attTn7 site in bacmid. Transformed colo-
nies were kanamycin, tetracycline and gentamycin resistant and could be identified by 
appropriate color. Intact bacmid vector contains a LacZα gene that allows digestion of 
chromogenic substrate, X-gal, under IPTG inducer conferring a blue color. A vector 
with recombined sequence of interest, on the other hand, is white. Verification of se-
quence transposition in extracted Bacmid DNA was performed by PCR with M13 for-
ward and reverse primes and visualized on 7% agarose gel. PCR product of untrans-
posed Bacmid appears on 300 bp band, PCR product of pFastBac1 without an insert 
appears at 2300 bp band or higher depending on the size of target insert. Bacmid helper 
plasmid and RNA contamination levels were visualized with 5% gel electrophoresis. 
The helper plasmid appears at approximately 10 kb. RNA contamination shows on the 
bottom of DNA ladder, construct repeats with the least RNA contamination were cho-
sen. 
The recombinant bacmid vector was isolated and transfected into insect cells. SF9 cells 
were cultured in HyClone SFX-insect media at 27ºC in a shaking incubator and subcul-
tured every 72 hours at precisely same time. The cells were transfected with 1-2 micro-
liters of bacmid DNA with Cellfectin reagent (Thermo Fisher Scientific, 10362100) in 
6-well plates. The virus expansion was carried out every 3 days from P1 to P2 by cen-
trifugation (4 000g, 1 min, +4ºC) of infected cells and collection of virus containing 
supernatant. The concrete manual can be obtained from Invitrogen (cat. number 10359-
016) Bac-to-Bac Baculovirus expression system. SF9 cells infection was done at 1% 
virus concentration. Virus stocks were stored t +4ºC up to six months. Test production 
of target proteins was carried out at 5% or 10% P3 virus concertation in 50 mL SF9 cell 
cultures at 4-5 x 106 cells/mL density.  
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Protein purification was conducted by the means of His-tag NiNTA resin beads. Test 
production cell cultures were collected by centrifugation (4 000g, 3 min, +4ºC) and re-
suspension in His lysis buffer (20 mM Tris pH 8 or 8.5, 500 mM NaCl, 20% glycerol, 
30 mM imidazole) with the following protease inhibitors: Sodium Vanadate (10 
µL/mL), Aprotinin (6 µL/mL) and PMSF (10 µL/mL). For proper lysis cells were rotat-
ed for 45 minutes at +4ºC and sonicated 3 times for 30 seconds in 5-seconds pulses at 
29% amplitude. Lysed cells were centrifuged at 10 000g for 1 hour. The NiNTA beads 
were washed 3 times with lysis buffer without inhibitors. The supernatant containing 
protein mixture was added to the washed beads and rotated for 2 hours at +4ºC. The 
beads were then washed 3 times to remove the unbound proteins and the protein of in-
terest was eluted 3 times with elution buffer (lysis buffer with 0.25 M imidazole). The 
purified proteins were verified by running on 10% SDS-PAGE gels with 4 x SDS sam-
ple buffer and dyed with instant blue for ≥ 30 minutes. 
2.3 Mammalian cell culture, transfection and Western Blotting 
Human fibrosacroma gamma2a cells were chosen for in cell experiments due to endog-
enous JAK2 deficiency. The cells were cultured in Dulbeco’s Modified Eagle Medium 
with 10% FBS, 0.5% PenStrep and 1% Glutamate and subcultured every 3-4 days. 
Twenty-four hours before transfection cells were seeded in 6 well plates at 1-2 x105 
cells/well (24-well plate 5 x104 cells/well). Cells were transfected with Fugene HD 
(Roche) according to manufacturer’s instructions with 600 and 1200 ng of DNA per 
well (75-150 ng in 24-well plate). After 24-48 hours, the cells were lysed with lysis 
buffer (50 mM TRIS-HCl, pH 8, 150 mM NaCl, 100 mM NaF, 10% (v/v) glycerol, 1% 
(v/v) Triton-X) containing protease inhibitors (Sodium Vanadate, Aprotinin, Pepstatin 
and PMSF). The expression of the constructs of interest and protein phosphorylation 
was analyzed with Western blotting with anti-pJAK2 1007 and 1008 (Cell Signaling 
Technology) and anti-His antibodies (Invitrogen).  
2.4 Cell labelling 
Fluorescence resonance energy transfer was performed in live and fixed gamma2a cells. 
For live cell experiments, the cells were seeded in glass-bottomed cell dishes with cover 
slips (35mm) in phenol red free medium to achieve 40-50% confluency at the moment 
of transfection (1-2x105cell/well). For fixed cell experiments, the cells were seeded at 
the same density in 6-well plates containing coverslips. Transfection was followed by 
48 hours incubation period. Cells were washed 2 times with 1-2 mL of prewarmed la-
belling buffer -  1x Hank’s Balanced salt solution (HBSS, Thermo Fisher Scientific, 
14025092). FlasH-EDT2 (664.5 g/mol) probe (Santa Cruz Biotechnology, 212118-77-9) 
was diluted in dimethyl sulfoxide (DMSO) to 1 mM concentration and the stocks were 
stored in 10 µL aliquots at -20ºC protected from light. 25 mM of 1,2-ethanedithiol 
(EDT) was diluted in DMSO right before labeling. Per sample: 1 µL of 25 mM EDT 
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and 1 µL of 1 mM FlasH were incubated protected from light for 5-10 minutes. 
FlasH/EDT was mixed with 100 µL HBSS and incubated for 5 minutes. The remaining 
900 µL of HBSS was added to the mixture to obtain final FlasH concentration of 500 
nM. HBSS was aspired from cells, FlasH-EDT2 HBSS mixture was added and incubat-
ed for 1-1.5 hours at 37ºC protected from light. To remove unbound label the labeling 
solution was replaced with 250 µM EDT and the cells were incubated for 10-15 min at 
37ºC protected from light. After incubation, the cells were washed 2-3 times with pre-
warmed HBSS. If the cells were imaged immediately they were left in HBSS, else cells 
were kept in phenol red free complete medium for up to 48 hours.  
2.5 Fixing cells 
Labeled cells were fixed using 4% paraformaldehyde. The coverslips were washed 2 
time with room temperature phosphate buffered saline (PBS) and incubated with freshly 
prepared 4% paraformaldehyde for 10 minutes at room temperature. Cells were washed 
again with PBS and mounted on glass slides. The slides were washed with 100% etha-
nol. One drop of mounting medium was applied to the center of the slide and the co-
verslips were placed cells down onto the glass slides. The mounted slides were cured for 
24 hours at room temperature in a dry and dark area and store at 4ºC for up to a month.  
2.6 Microscopy 
Fluorescence time series imaging and FRET by acceptor photobleaching were per-
formed with Zeiss LSM 780 confocal microscope. The microscope was equipped with 
an incubator for maintenance of physiological conditions during the procedures. 62X 
water based immersion objective with 1.2NA was used for live cell imaging and 62X oil 
based immersion objective with 1.4NA was used for fixed cell imaging. The microsco-
py setup was kept constant in every experiment. Acquisition was performed at 12 Bit 
image. Gain (sensitivity of photomultiplier) was set at 500 – 800, pinhole was kept at 90 
µm based on the best noise to fluorescence ratio, digital offset at zero, digital gain at 
1.1, laser power was kept low at 1-2% to minimize photo bleaching of the samples dur-
ing imaging.  
Time lapse fluorescent imaging was carried out over a 20-30 cycles (1 – 1.5-hour peri-
od) with 3-minute increments between imaging. FlAsH-EDT2 was added after the first 
cycle. Measurements were done in four channels: CFP (405-455 nm), FRET (405-520 
nm), FlAsH (514-565 nm) and bright field. FRET by acceptor photobleaching was per-
formed with time series of 15 cycles with 0 milliseconds intervals between imaging 
with number of iterations equal 50. Bleaching was started after the first 5 cycles. Zoom 
factor was kept equal at 3. Frame size small (512XY), high resolution at optimal, aver-
aging at 1 and scanning speed at maximum to overrun the diffusion of the POI. Bleach-
ing was done to full cells and a specific region of interest for intensity data extraction 
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was selected at image processing stage. The image processing was done with ImageJ 
software.  
2.6.1 FRET calculations 
Upon addition of FlaH-EDT2 the CFP fluorescence intensity in the expressed constructs 
in quenched provided that the probe is specifically bound at tetracysteine motif. When 
FlasH-EDT2 is bleached the donor fluorescence recovers to an extent dependent of the 
distance between two fluorophores. The FRET efficiency is calculated with the follow-
ing formula.  
𝐸 =
𝐼𝑎𝑓𝑡𝑒𝑟 − 𝐼𝑏𝑒𝑓𝑜𝑟𝑒
𝐼𝑎𝑓𝑡𝑒𝑟
×100,                                              (1) 
where E is apparent FRET efficiency in %, Iafter is the mean donor intensity of following 
5 measurements after bleaching and Ibefore is the mean donor intensity of 5 measure-
ments before bleaching.  
2.7 Statistical analysis 
Statistical analysis was performed with SPSS software. The statistical significance (p-
value) of changes in mean FRET intensity between constructs of interest relative to con-
trol and between wild-type and VF mutants was calculated with Student t-test. The 
normality of data was assessed with Shapiro-Wilk test and analysis of z-values of skew-
ness and kurtosis.  
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3. RESULTS 
3.1 Construct expression and phosphorylation 
Expression and activation of +/- VF constructs was analyzed by Western Blotting 
against anti-pJAK2 Y1007 and Y1008 antibodies and His-tag antibodies. The constructs 
were transfected at two concentrations: a – 75 ng/well, b – 150 ng/well. A negative con-
trol of untransfected cells was used to identify background noise. The constructs are 
expressed in mammalian cells and appropriate size was observed in western blot. How-
ever, the expression levels vary and the N-terminus CFP fusion proteins appear to be 
expressed more. This difference can be addressed by improving the quality of the plas-
mid and by titration of DNA concentrations to identify the suitable concentration for 
transfection. It is evident from Figure 6 that phosphorylation of JH1 Y1007 and Y1008 
is not consistent among the constructs either, but is the same between wild type and 
corresponding pathogenic versions. Construct 2 and control 2 appear to be activated to a 
small degree in both wild type and VF mutants. It should be noted that the expression of 
constructs with C-terminus CFP is lower in both +/- VF, and due to this, a higher con-
centration of DNA was used for FRET experiments. 
 
 Expression and activation of constructs with and without VF 
 
3.2 Protein purification 
Protein purification of five constructs of interest without V617F mutation was carried 
out along with 2 positive controls which could previously be successfully purified. Posi-
tive controls used in the experiment were two wild type JH2-JH1 domains of JAK2 
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(positive control 1) and one wild type JH1 domain of JAK3 (positive control 2). Preced-
ing baculovirus production, generated bacmids were analyzed for gene of interest se-
quence insertion with 5% agarose gel analysis and PCR. While it is almost impossible 
to visualize the entire bacmid vector with gel electrophoresis due to its very large size 
(136 kb) the baculovirus expression system includes another plasmid, a helper plasmid, 
bearing a transposase enzyme which facilitates in trans transposition (Barry 1988). The 
helper plasmid is over 10 kb in size but is still visible when run on low density 5% aga-
rose gel as shown in Figure 7, A. High molecular weight bacmid plasmid is too large to 
depart from the wells on agarose gel but can still be distinguished right underneath 
them. The insertion of sequence of interest was verified by PCR with M13 primers. The 
expected size of PCR product of constructs 1, 2 and 3 (marked as 1, 2, 3 in the Figure 7, 
B) and controls 1 and 2 (denoted as ctrl 1 and ctrl 2) was 4800 bp, 4100 bp of positive 
control 1 and 3200 bp of positive control 2. The DNA bands of the correct size appear 
above a bright 3000 bp ladder band in Figure 7, B. 
The expected protein molecular weight of the constructs was 100 kDa which can be 
found on the SDS page ruler ladder right above the black 70 kDa mark. The size of pos-
itive control 1 was 70 kDa and positive control 2 was 35 kDa. Samples for SDS-PAGE 
gel were taken after every step of protein purification for monitoring errors during the 
procedure. The first lane on the gels corresponds to whole cell lysate after sonication. 
Second lane represents the sample of cell pellet after centrifugation of cell lysate. The 
third lane represents the unbound protein after incubation with NiNTA beads and cen-
trifugation. The forth lane shows presence of any protein after the first washing step. 
The lanes from 5 to 8 are the 3 elution steps and the last lane are the beads suspended in 
elution buffer.  
As it can be seen from the images (Figure 7, C), purification of the target constructs was 
unsuccessful. The arrows indicate where the protein band would be expected to be. By 
comparing to the positive controls, we can notice a considerable amount of protein al-
ready in the whole cell lysate and pellet samples. As there’s almost no protein visible in 
lanes 3 and 4 we can be certain that the whole purification procedure went well without 
losing any protein. Nevertheless, it is no surprise that the constructs failed to purify. It 
has been previously noted that even one amino acid change can destabilize the entire 
protein (Babon et al. 2014). Here we had six amino acids change and a bulky fluores-
cent protein attached to either sides of JAK2 JH2-JH1 domains. While designing the 
constructs the sites of structural divergence among typical tyrosine kinases were identi-
fied for insertion of the tetracysteine motif. Such divergence was thought to presumably 
exert no particular effect on the structure and function of the proteins. By looking at 
Figure 6 it is evident that the constructs are expressed in mammalian cells meaning that 
it is the protein production conditions that need optimizing to achieve protein yields. 
Temperature as well as incubation time of insect cells with the virus can be varied be-
tween 22 to 27 ºC and between 48 to 72-hours incubation time. The concentration of 
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virus during infection can also play a role in protein production, therefore testing the 
production at 1, 5 and 10% virus could bring a different outcome. When attempting to 
purify and crystalize JAKs it is common to create kinase inactive mutants by introduc-
ing a kinase inactivating mutation (as D1023N in TYK2) that confers a more stable pro-
tein (Lupardus et al. 2014). Furthermore, introduction of tetracysteine motif could have 
exposed some hydrophobic residues that caused insolubility of the constructs. Our JH2-
JH1 sequence started at 536 valine residue, yet it is also common that JH2-JH1 experi-
mental constructs are longer and start at 513 residue. 
 
  A) Agarose gel analysis of transposed bacmids helper plasmid and RNA 
contamination levels. B) PCR verification of Bacmid transposition. The size of 
construct of interest is 4800 bb, the size of positive controls 1 and 2 is 4100 and 
3200 bp, respectively. C) SDS-PAGE gels of purified constructs. The construct 
molecular weight is 100 kDa, the molecular weight of positive control 1 and 2 is 
70 and 35 kDa, respectively. The positions of purified protein bands are marked 
with black arrows. 
3.3 FRET 
3.3.1 Time lapse imaging 
In this study, we considered two ways of examining energy transfer between fluoro-
phores. The first method is direct monitoring of decrease in donor fluorescence intensity 
upon addition of the acceptor fluorophore. This method was described by Hoffmann et 
al. (2010) who observed an up to 50% decrease in CFP fluorescence intensity after the 
addition of FlAsH-EDT2 in their constructs. Time series imaging was performed for 
one hour with 3-minutes intervals between capturing. Testing of this method was im-
plemented only for constructs 1 and 2 and was aborted due to technical limitations, 
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however the results are presented below in Figure 8. In Figure 8, A and B the fluores-
cence intensity between constructs 1 and 2 and corresponding controls is presented. The 
graphs demonstrate that the CFP fluorescence intensity in constructs containing FlAsH-
binding motif starts to reduce right after the addition of the fluorescent dye. This is an 
anticipated event that indicates an occurrence of FRET between CFP and FLAsH-
EDT2. Construct 2 shows greater than 50% change in the CFP intensity, whereas con-
struct 1 displays a 20% reduction after which it returns to the original state and doesn’t 
change anymore. Both controls, on the other hand, demonstrate a regular increase in 
donor intensity, being a mere 20% change in control 1 and remarkable 100% change in 
control 2. These changes, however, are not attributes of any biological or physical pro-
cesses of energy transfer that we were aiming to see. These changes occurred due to the 
imperfect focus system of the microscope that failed to keep the sample continuously in 
focus during time-lapse imaging.  When left alone the shifting of focus caused the entire 
image to dim leading to seeming quenching of CFP fluorescence intensity as in con-
struct 2. When the time series imaging was interrupted and the focus adjusted back to 
being sharp and crisp, the donor fluorescence intensity returned back to being around 
the initial values as in construct 1 after the eighth cycle. Another factor contributing to 
loss of focus is cell movement within the scanning z-plane and migration between the 
planes. The latter reason in particular caused troubles in continuous measurements of 
CFP fluorescence since not every cell in the chosen area was fluorescent. Therefore, 
migration of CFP expressing cells resulted in ‘reduced’ CFP fluorescent intensity of the 
whole area. Unfortunately, this issue can only be addressed by using more complicated 
instrumentation since fixing cells will not anymore allow proper labeling. Coincidental-
ly, an opposite effect of loss of focus was observed in both controls. In case of control 2 
the focus was disturbed right after the addition of the label, but was adjusted after the 
second cycle after which the CFP fluorescence intensity fluctuated at around 2. 
Even though this method did not yield any useful results it allowed optimization of the 
labeling and washing procedures. The suitable incubation time with FlAsH-EDT2 could 
be identified. The time length depended on the position of the fluorescent tag motif, 
being longer for the constructs that harbored the tag in their interior loops. The satura-
tion of FlAsH fluorescence, for instance, was observed quicker in construct 1 in com-
parison to construct 2 or 3, due to the terminal location of the tag, which allows for easy 
access by fluorescent dye. In Figure 8, C and D, the representative images of labeled 
cells after 1 – 1.5-hours incubation and before washing are presented. Once the desired 
fluorescence was reached the cells were subjected to washing with 1,2-ethanedithiol, an 
antidot for FlAsH-EDT2. Because FlAsH-EDT2 has a tendency to bind unspecifically 
to cysteine rich proteins as well as within hydrophobic protein compartments, addition 
of excess amounts of dithiols binds the unbound and loosely bound bisarsenic com-
pounds. As it can be seen in images of FlAsH-EDT2 after wash and with only CFP, the 
FlAsH fluorescence of CFP expressing cells is higher than in the surrounding untrans-
fected cells. In the controls, however, the FlAsH-EDT2 intensity after washing is uni-
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form among untransfected and transfected, CFP expressing cells. This demonstrates that 
we achieved specific labelling of tetracysteine tag.  
 
  A) and B) Time lapse measurements of CFP fluorescence intensity. The 
measurements were performed over 15 cycles of 3 minutes by monitoring the in-
tensity of FRET donor. The results are normalized to the first value after sub-
traction of background signal and presented with standard error. C) and D) 
Representative images of specificity of labeling with FlAsH-EDT2. The cells ex-
hibited saturation in 514-565 nm channel (FlAsH channel) after 1-1.5h of incu-
bation with FlAsH-EDT2. The unspecific binding was reduced by a washing step 
with 1,2-ethanedithiol (EDT). The turquoise fluorescent cells in the lowest row 
of construct 1 and 2 contain a tetracysteine biding motif, whereas the controls 
do not. The presence of tetracysteine binding motif confers a considerably 
brighter yellow fluorescence indicative of specific labeling.  
3.3.2 FRET by acceptor photobleaching 
Acceptor photobleaching is a popular FRET approach for qualitative evaluation of bio-
logical processes on as small as under 10 nm scale. It is a relatively straightforward way 
to analyze stable as well as transient protein-protein interactions. Here, we analyzed 
FRET efficiency by carrying out measurements of donor fluorescence recovery after 
acceptor photobleaching in CFP – FlAsH-EDT2 FRET pair. The results are a mean of 
three independent experiments per construct, each performed on 20-30 cells. Cells with 
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approximately equal CFP-expression levels were selected to facilitate a comparative 
analysis. The t- and p-values of FRET efficiency between +/- VF constructs are present-
ed in figures 9 and 10 with degrees of freedom shown in brackets. The p-value of FRET 
efficiency difference between the constructs and their corresponding controls was < 
0.001 in every situation. FRET efficiency measurements by acceptor photobleaching 
were carried out in both, live and fixed cells. Live cells measurements were performed 
under physiological conditions in 5% CO2 air at 37
oC.  
 
 FRET efficiency by acceptor photobleaching in intact cells. A) Construct 1 
+/- VF, B) construct 2 +/- VF, C) construct 3 +/- VF. The t- and p-values are 
obtained with two-sample t-test and presented for constructs with and without 
VF mutation. The significance of FRET efficiency difference between constructs 
and controls is more than 99.9%. D), E) and F) representative images of label-
ing specificity with FlAsH-EDT2. 
Figure 9, A, B and C demonstrate the FRET efficiency of constructs 1, 2 and 3 with and 
without V617F mutation and the corresponding controls in living cells. Figure 9, D, E 
and F contain representative images of labelled cells depicting specific binding of 
FlAsH to tetracysteine regions. The FRET efficiency is presented as efficiency of re-
covery of fluorescence intensity of the donor after photobleaching of the acceptor in a 
selected ROI of arbitrary size. It is evident that donor fluorescence recovery is signifi-
cantly higher (p-value < 0.001) in constructs containing tetracysteine sequence in com-
parison to controls, which means that FRET between CFP and FlAsH-EDT2 indeed 
takes place in our constructs. The difference in FRET efficiency between constructs 
with and without VF, however, is statistically significant only in construct 1 with p-
value < 0.001. Construct 1 VF exhibits lower FRET efficiency, which implies that in-
troduction of VF mutation causes the distance separating two fluorophores to increase. 
No significant changes of FRET efficiency between +/- VF in constructs 2 and 3 was 
observed indicating no considerable effect of this mutation to the interior of our protein 
of interest. It can be noticed, however, that the standard deviation of FRET efficiency in 
cells transfected with constructs 2 and 3 +/- VF is markedly large. This can be explained 
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by the fact, that despite strict adherence to standardized protocol for labeling with 
FlAsH-EDT2 it was not always possible to achieve equal labeling intensity on different 
days. The labelling intensity was compared by calculating CFP/FlAsH-EDT2 intensity 
ratio. The reason for such variations is still unclear since no deviations from optimal 
concentrations of reagents, DNA or number of seeded cells occurred. To overcome this 
issue, it was decided to conduct FRET efficiency measurements in fixed cells that were 
labeled and fixed simultaneously on the same day. Another modification to our experi-
mental setup was to carry out whole cell photobleaching rather than of a specific region 
of interest. It caught our attention that photobleaching of a selected ROI resulted in im-
mediate attenuation of FRET following the first cycle after acceptor photobleaching. 
FRET attenuation can be attributed to diffusion of probe bound POI to the ROI that re-
sults in quenching of donor fluorescence (Karpova et al. 2003). It is worth pointing out 
that the immediate change was always higher between the fifth and sixth cycles (right 
before and right after bleaching) than the mean of five cycles before and after bleaching.  
Bleaching of the whole cell was deemed to prevent such problem and show a more sta-
ble donor fluorescence recovery. If this problem would not be eliminated disappearance 
of FRET in the cycles following bleaching could have a certain different meaning 
(Karpova and McNally 2006). 
  
31 
 
 
 FRET efficiency by acceptor photobleaching in fixed cells. A) Con-
struct 1 +/- VF, B) construct 2 +/- VF, C) construct 3 +/- VF. The t- and p-
values are obtained with two-sample t-test and presented for constructs with and 
without VF mutation. The significance of FRET efficiency difference between 
constructs and controls is more than 99.9%. D) A cartoon representation of 
JAK2 JH2 (in orange) and JH1 (in green) domains with tetracysteine motives 
highlighted in red, V617 enclosed in transparent spheres and interactions of 
fluorophores in every construct are indicated by arrows.  
Figure 10, A, B and C present the results of FRET efficiency measurements by acceptor 
photobleaching in fixed cells. It can be seen that by implementing measurements in 
fixed cells we were able to achieve a reduction in the measurement deviation among 
samples. The average labelling intensities between the constructs with and without 
V617F mutation were also comparable being 0.72 and 0.71 for construct 1 +/- VF, 1.86 
and 1.84 for construct 2 +/- VF and 0.80 and 0.71 for construct 3 +/- VF. It might be 
noticed, though, that the overall signal of CFP fluorescence is lower in fixed cells, yet 
we still observe a significant difference (p-value < 0.001) between constructs with tetra-
cysteine motif and controls without thereof. The change in FRET efficiency in construct 
1 with VF is now, however, almost indistinguishable from construct 1 without VF with 
only 88% confidence level of FRET efficiency decrease. Even though this result contra-
D 
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dicts what we observed in intact cells such outcome could be anticipated due to several 
reasons. Most importantly, it should be pointed out that in construct 1 the fluorophores 
are attached through short, but still quite flexible linkers. Such flexibility allows easy 
reorientation of the fluorophores and even if a small conformational change occurred 
inside the protein the effect would not necessarily be prominent. Such flexibility, on the 
other hand, leads to comparatively higher overall FRET efficiency than in constructs 2 
and 3. This can be attributed to higher probability of correct positioning of transitional 
dipoles of two fluorophores. Nevertheless, statistically significant change in FRET effi-
ciency can now be recognized in constructs 2 and 3 between wild type and V617F mu-
tation. An increase in FRET efficiency is detected (p-value = 0.007) in construct 2 with 
VF indicating that introduction of comparably large phenylalanine residue results in 
distance reduction by 0.54. Construct 3 VF, on the contrary, demonstrates a decrease in 
FRET efficiency (p-value = 0.037) by 0.71 implying a reverse effect on separation dis-
tance.  
Despite seemingly complicated outcome of this study, our results can be interpreted in a 
reasonable way. Figure 10, D illustrates how mutation of 617 valine to phenylalanine 
(highlighted by transparent spheres) induces a conformational change between JH2 and 
JH1 domains in JAK2. The representation of interdomain interactions in Figure 10, D is 
of course not precise since CFP is missing from the picture, but it gives a relative under-
standing of occurring alterations. It can be seen that the increase in distance between the 
C-terminus of JH1 and 726-728 residues of JH2 can lead to the decrease in distance 
between the N-terminus of JH2 and residues 1053-1055 due to their positioning oppo-
site to each other. The conformational change induced by V617F mutation in construct 
2 directs the N-lobe of JH2 domain towards the hinge region in JH1 presumably affect-
ing its entire catalytic site. Activation of JAKs is underlined by expulsion of activation 
loop from the catalytic site. Therefore, the hyperactivatory effect of V617F mutation 
can be associated with rotation of JH2 N-lobe towards the catalytic loop in JH1 result-
ing in physical expulsion of A-loop and exposure of Y1007 and Y1008 for phosphoryla-
tion. Our finding plays an important role in trying to decipher how mutation of one 
amino acid leads to non-stop activity of such crucial enzyme in organismal homeostasis 
as JAK2. 
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4. DISCUSSION 
Protein-protein interaction studies have been performed in vitro with isolated proteins 
now for many years (Dwane and Kiely 2011). The method is advantageous in many 
terms. For instance, controlled protein concentration and, hence, peptide tag concentra-
tion, sensitivity of measuring devices that can detect even the weakest interactions and 
independence of expression levels unlike in cell experiments (Phizicky and Fields 
1995). However, due to difficulty of isolation of certain proteins and their insolubility 
(Karpova and McNally 2006), the in vitro approach is at times unavailable. To over-
come this issues the fluorescence resonance energy transfer approach in cells is capable 
of detecting protein-protein interactions on the 10 nm scale (Karpova and McNally 
2006; Vaiyapuri et al. 2015; Abraham 2015). FRET is based on the intrinsic properties 
of a fluorophore in an excited state to transfer some of its energy to another fluorophore 
provided sufficient spectrum overlap (Abraham et al. 2011). Traditionally different var-
iants of green fluorescence proteins were used in FRET analysis, however due to their 
large molecular weight (approximately 27 kDa) these fluorescent markers can alter the 
functionality and native structure of the target protein (Adams et al. 2002; Hoffmann et 
al. 2010). In the first paper reporting CFP-FlasH based FRET (Hoffmann et al. 2005) it 
was demonstrated that use of YFP-CFP FRET pair via insertion of YFP to an intracellu-
lar loop of A2A-adenosine receptor in addition to CFP at the C-terminus of the receptor 
completely perturbed the signaling function of the protein. To tackle this issue genet-
ically encoded tags in conjunction with small fluorescent molecule dyes were invented 
that can replace the use of cumbersome fluorescent proteins and allow the study of near-
ly unchanged proteins (Soh 2008).  
There exist several methods to FRET measurements, each with its own advantages. 
While FRET by lifetime imaging enables the most accurate analysis, FRET steady state 
measurements by acceptor photobleaching is a widely-accepted technique due to its 
straightforward nature (Karpova and McNally 2006; Abraham 2015). With an easy set-
up, as in our study, it allows visualization of a few nanometer changes in protein con-
formation. With a more vigorous system the changes can be assessed quantitatively 
providing invaluable knowledge of spatial transposition and localization of biomole-
cules of interest. Despite the requirements for excessive controls for normalization and 
calibration such system helps to achieve quantification of relevant FRET efficiency and 
separation distances (Karpova et al. 2003; Karpova and McNally 2006; Zal and 
Gascoigne 2004). In our study, we implement a simpler approach to analysis of the ori-
entational changes between pseudokinase and kinase domains of JAK2 in wild type and 
under a function disruptive mutation. The mutation of interest in this work is V617F 
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which was identified as a major cause for 95% of polycythemia vera incidences and 
60% of essential thrombocythemia (Hammarén et al. 2015; Klampfl et al. 2013). Due to 
an effect of so called allele burden addressing the disorders caused by V617F mutation 
as early as possible is crucial to prevent its progression into more severe diseases that 
eventually lead to leukemia (Passamonti and Rumi 2009).  
Here, we demonstrated a conformational change induced by the introduction of V617F 
mutation in the studied constructs. Phenylalanine is a considerably large amino acid that 
has previously been shown to modify the α-helix in the N-lobe of JH2 domain 
(Bandaranayake et al. 2012). In particular, the replacement of valine at 617 by phenylal-
anine resulted in rigidification of α-helix due to attractive aromatic interactions of three 
phenylalanines at 594, 595 and 617 positions. Moreover, the α-helix was found to be 
extended by a turn at its amino-terminus which is proximal to the N-lobe of JH1 
(Bandaranayake et al. 2012). Our results complement these findings by showing that 
V617F mutation causes the N-lobe of JH2 to turn towards the hinge region in JH1 by 
juxtaposing the N-terminus of JH2 to the insertion loop of JH1. Such change is accom-
panied by separation of the C-terminus of JH1 from the 726-728 residues in the C-lobe 
of JH2. It is possible that this conformational change has an influence on the catalytic 
site of JH1 domain resulting in constitutive activation of JAK2. Furthermore, in earlier 
studies, insertion loop of kinase domain was identified to exert a unique function in 
JAK kinases and recognized as a possible regulator of autophosphorylation activity and 
interdomain interaction with FERM domain (Boggon et al. 2005; Lucet et al. 2006). By 
placing a tetracysteine tag at position 1053-1055, right before the start of the insertion 
loop of JAK2 kinase domain, we observed a positional shift in this important regulatory 
site.  
Further investigation of this subject is required to unravel more exact structural altera-
tions imposed by V617F mutation. Using the system established through this work as a 
foundation it is possible to resolve other unexplored questions. For instance, our con-
cept could be strengthened by observing the results of reversing the effect of V617F 
mutation using JAK2 inhibitors, such as ruxolitinib (Kogan et al. 2015), or by introduc-
tion of kinase deactivating mutation. While these methods will not necessarily demon-
strate the same levels of FRET efficiency as in our wild type constructs they might help 
realize what is essential for disruption of suppressory effect of JH2 on JH1 domain 
caused by V617F mutation. The simple site-directed mutagenesis procedure can be used 
to insert the tetracysteine tag into other locations of our protein of interest. In fact, when 
the tetracysteine tag system was first developed by Griffin et al (1998) they embedded 
the four cysteines at the i, i+1, i+4, and i+5 loci of a helix to create a parallelogram that 
could perfectly bind FlAsH-EDT2. Such approach can be implemented to see how the 
position of α-helix in JH2 changes in pathogenic constructs.  
To further advance our knowledge in this matter, the same approach can be used in full-
length JAK2 and by generating stably transfected cell lines to avoid the overexpression 
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of protein in transient transfection and to reduce toxicity. Using full-length protein con-
structs would also allow to ensure the unperturbed kinase activity of JAK2 after intro-
duction of the tetracysteine motif and fusion with FPs. Presence of the FERM and SH2 
domains responsible for receptor association would enable monitoring of receptor and 
STAT phosphorylation (Chrencik et al. 2010; Yamaoka et al. 2004). With the current 
experimental setup, it is unclear whether the function of JH2-JH1 domains was dis-
turbed by addition of fluorescent tags. To our surprise, we observed no phosphorylation 
of 1007 and 1008 tyrosines in VF constructs 1 and 3. On the other hand, the construct 2 
without VF appeared phosphorylated implying less inhibitory interactions between JH2 
and JH1. Such effect could be observed due to our specific construct design. Neverthe-
less, it can be concluded that such phosphorylation patterns are caused by addition of 
CFP and independent of tetracysteine tag since similar effect was detected in controls 1 
and 2 that did not possess FlAsH binding site. Notwithstanding this fact, our results are 
still comparable because phosphorylation levels are the same in wild type and corre-
sponding VF constructs but we do once again encounter the issue of FPs inconvenient 
size. To overcome this problem, a different approach can be utilized that evades in-
volvement of FPs. FlAsH-EDT2 and his-tag labelled by Ni-NTA conjugated fluorescent 
reporters has been successfully shown as a donor-acceptor pair in FRET measurements 
(Krishnan, Szymanska, and Gierasch 2007). As a drawback, fluorescent labeling of his-
tag results in undesired amounts of unspecific binding (Christian R. Goldsmith et al. 
2005; Lata et al. 2006), however the protein-protein interactions could be differentiated 
by FRET. To further ensure that the measured cells are actually transfected another flu-
orescent reporter with emission somewhere in infra-red spectrum could be added that 
would not overlap the excitation/emission spectrum of FRET pair fluorescent labels.  
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5. CONCLUSION 
Using a FRET based approach to investigation of interdomain interactions and confor-
mational dynamics of JAK2 pseudokinase and kinase domains we identified novel 
changes induced by V617F mutation to JAK2 wild type structure. We revealed that mu-
tation of 617-valine to phenylalanine leads to reorientation of JH2 N-lobe towards the 
catalytic site of kinase domain thereby increasing the distance between the C-terminus 
of JH1 and the 726-728 residues in the C-lobe of JH2. We believe that such changes can 
underlie the hyperactivatory effect of V617F mutation that disrupts the basal inhibition 
of catalytic domain by pseudokinase domain. Further studies could shed more light onto 
the detrimental effect of V617F mutation enabling development of mutant-specific, 
more efficacious pharmaceutical agents. 
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APPENDIX A 
Table 1. JH2-JH1 DNA and amino acid sequences.  
 
535 
atggtgtttcacaaaatcagaaatgaagatttgatatttaatgaaagccttggccaaggc 
 M  V  F  H  K  I  R  N  E  D  L  I  F  N  E  S  L  G  Q  G 
 
554 
 
555 
acttttacaaagatttttaaaggcgtacgaagagaagtaggagactacggtcaactgcat 
 T  F  T  K  I  F  K  G  V  R  R  E  V  G  D  Y  G  Q  L  H  
 
574 
 
575 
gaaacagaagttcttttaaaagttctggataaagcacacagaaactattcagagtctttc 
 E  T  E  V  L  L  K  V  L  D  K  A  H  R  N  Y  S  E  S  F 
 
594 
 
595 
tttgaagcagcaagtatgatgagcaagctttctcacaagcatttggttttaaattatgga 
 F  E  A  A  S  M  M  S  K  L  S  H  K  H  L  V  L  N  Y  G  
 
614 
 
615 
gtatgtgtctgtggagacgagaatattctggttcaggagtttgtaaaatttggatcacta 
 V  C  V  C  G  D  E  N  I  L  V  Q  E  F  V  K  F  G  S  L  
 
634 
 
635 
gatacatatctgaaaaagaataaaaattgtataaatatattatggaaacttgaagttgct 
 D  T  Y  L  K  K  N  K  N  C  I  N  I  L  W  K  L  E  V  A  
 
654 
 
655 
aaacagttggcatgggccatgcattttctagaagaaaacacccttattcatgggaatgta 
 K  Q  L  A  W  A  M  H  F  L  E  E  N  T  L  I  H  G  N  V  
 
674 
 
675 
tgtgccaaaaatattctgcttatcagagaagaagacaggaagacaggaaatcctcctttc 
 C  A  K  N  I  L  L  I  R  E  E  D  R  K  T  G  N  P  P  F  
 
694 
 
695 
atcaaacttagtgatcctggcattagtattacagttttgccaaaggacattcttcaggag 
 I  K  L  S  D  P  G  I  S  I  T  V  L  P  K  D  I  L  Q  E  
 
714 
 
715 
agaataccatgggtaccacctgaatgcattgaaaatcctaaaaatttaaatttggcaaca 
 R  I  P  W  V  P  P  E  C  I  E  N  P  K  N  L  N  L  A  T  
 
734 
 
735 
gacaaatggagttttggtaccactttgtgggaaatctgcagtggaggagataaacctcta 
 D  K  W  S  F  G  T  T  L  W  E  I  C  S  G  G  D  K  P  L  
 
754 
 
755 
agtgctctggattctcaaagaaagctacaattttatgaagataggcatcagcttcctgca 
 S  A  L  D  S  Q  R  K  L  Q  F  Y  E  D  R  H  Q  L  P  A  
 
774 
 
775 
ccaaagtgggcagaattagcaaaccttataaataattgtatggattatgaaccagatttc 
 P  K  W  A  E  L  A  N  L  I  N  N  C  M  D  Y  E  P  D  F  
 
794 
 
795 
aggccttctttcagagccatcatacgagatcttaacagtttgtttactccagattatgaa 
 R  P  S  F  R  A  I  I  R  D  L  N  S  L  F  T  P  D  Y  E  
 
814 
 
815 
ctattaacagaaaatgacatgttaccaaatatgaggataggtgccctggggttttctggt 
 L  L  T  E  N  D  M  L  P  N  M  R  I  G  A  L  G  F  S  G 
 
834 
 
835 
gcctttgaagaccgggatcctacacagtttgaagagagacatttgaaatttctacagcaa 
 A  F  E  D  R  D  P  T  Q  F  E  E  R  H  L  K  F  L  Q  Q 
 
854 
 
855 
cttggcaagggtaattttgggagtgtggagatgtgccggtatgaccctctacaggacaac 
 L  G  K  G  N  F  G  S  V  E  M  C  R  Y  D  P  L  Q  D  N 
 
874 
 
875 
actggggaggtggtcgctgtaaaaaagcttcagcatagtactgaagagcacctaagagac 
 T  G  E  V  V  A  V  K  K  L  Q  H  S  T  E  E  H  L  R  D 
 
894 
 
895 
tttgaaagggaaattgaaatcctgaaatccctacagcatgacaacattgtaaagtacaag 
 F  E  R  E  I  E  I  L  K  S  L  Q  H  D  N  I  V  K  Y  K  
 
914 
 
915 
ggagtgtgctacagtgctggtcggcgtaatctaaaattaattatggaatatttaccatat 
 G  V  C  Y  S  A  G  R  R  N  L  K  L  I  M  E  Y  L  P  Y 
 
934 
 
935 
ggaagtttacgagactatcttcaaaaacataaagaacggatagatcacataaaacttctg 
 G  S  L  R  D  Y  L  Q  K  H  K  E  R  I  D  H  I  K  L  L 
 
954 
 
955 
cagtacacatctcagatatgcaagggtatggagtatcttggtacaaaaaggtatatccac 
 Q  Y  T  S  Q  I  C  K  G  M  E  Y  L  G  T  K  R  Y  I  H  
 
974 
 
975 
agggatctggcaacgagaaatatattggtggagaacgagaacagagttaaaattggagat 
 R  D  L  A  T  R  N  I  L  V  E  N  E  N  R  V  K  I  G  D 
 
994 
 
995 
tttgggttaaccaaagtcttgccacaagacaaagaatactataaagtaaaagaacctggt 
 F  G  L  T  K  V  L  P  Q  D  K  E  Y  Y  K  V  K  E  P  G 
 
1014 
 
1015 
gaaagtcccatattctggtatgctccagaatcactgacagagagcaagttttctgtggcc 
 E  S  P  I  F  W  Y  A  P  E  S  L  T  E  S  K  F  S  V  A 
 
1034 
 
1035 
tcagatgtttggagctttggagtggttctgtatgaacttttcacatacattgagaagagt 
 S  D  V  W  S  F  G  V  V  L  Y  E  L  F  T  Y  I  E  K  S  
 
1054 
 
1055 
aaaagtccaccagcggaatttatgcgtatgattggcaatgacaaacaaggacagatgatc 
 K  S  P  P  A  E  F  M  R  M  I  G  N  D  K  Q  G  Q  M  I  
 
1074 
 
1075 
gtgttccatttgatagaacttttgaagaataatggaagattaccaagaccagatggatgc 
 V  F  H  L  I  E  L  L  K  N  N  G  R  L  P  R  P  D  G  C 
 
1094 
 
1095 
ccagatgagatctatatgatcatgacagaatgctggaacaataatgtaaatcaacgcccc 
 P  D  E  I  Y  M  I  M  T  E  C  W  N  N  N  V  N  Q  R  P 
 
1114 
48 
 
1115 
tcctttagggatctagctcttcgagtggatcaaataagggataacatggctggatga 
 S  F  R  D  L  A  L  R  V  D  Q  I  R  D  N  M  A  G  - 
 
1133 
 
 
 
 
 
 
